Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 6:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 13,273 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Infusion Clear all
Completed Phase 3 Interventional Results available

rVWF IN PROPHYLAXIS

NCT02973087
View directory record Official record
Conditions
Von Willebrand Disease
Interventions
von Willebrand factor (Recombinant), Antihemophilic Factor (Recombinant)
Biological
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
8
States / cities
Loveland, Colorado • Gainesville, Florida • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2021 · Synced Oct 28, 2026, 6:34 PM EDT
Active, not recruiting No phase listed Observational

A Prospective Observational Study of TPIAT

NCT03260387
View directory record Official record
Conditions
Pancreatitis, Chronic, Pancreatectomy; Hyperglycemia, Pancreatitis
Interventions
TPIAT
Procedure
Lead sponsor
University of Minnesota
Other
Eligibility
Not listed
Enrollment
433 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
12
States / cities
San Francisco, California • Chicago, Illinois • Louisville, Kentucky + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 28, 2026, 6:34 PM EDT
Completed Not applicable Interventional Results available

Post-Op Rotator Cuff Pain Study With Subacromial Bupivacaine Infusion

NCT01126593
View directory record Official record
Conditions
Rotator Cuff Tear
Interventions
0.5% bupivacaine, Normal Saline
Drug
Lead sponsor
Orlando Health, Inc.
Other
Eligibility
18 Years to 90 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Nov 7, 2014 · Synced Oct 28, 2026, 6:34 PM EDT
Active, not recruiting Phase 3 Interventional

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

NCT06691984
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
Xaluritamig, Abiraterone, Enzalutamide, Cabazitaxel
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older · Male only
Enrollment
707 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
42
States / cities
Birmingham, Alabama • Duarte, California • Fullerton, California + 32 more
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 28, 2026, 6:34 PM EDT
Terminated Phase 1Phase 2 Interventional

A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors

NCT06257758
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumors, Breast Cancer, Recurrent Ovarian Cancer, Prostate Cancer
Interventions
VIO-01
Drug
Lead sponsor
Valerio Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
Lake Mary, Florida • Oklahoma City, Oklahoma • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Oct 28, 2026, 6:34 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Single Ascending Dose Safety and Tolerability of NTS-104 Healthy Adults

NCT05547438
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
NTS-104 TRIS, Placebo
Drug
Lead sponsor
NeuroTrauma Sciences, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 28, 2026, 6:34 PM EDT
Terminated Phase 2 Interventional

Phase 2 Study to Assess the Efficacy & Safety of Gemcitabine + Nab Paclitaxel With or Without Dociparstat in Metastatic Pancreatic Cancer Patients

NCT01461915
View directory record Official record
Conditions
Metastatic Pancreatic Cancer
Interventions
Nab paclitaxel, Gemcitabine, Dociparstat
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
16
States / cities
Scottsdale, Arizona • Burbank, California • Greenbrae, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2022 · Synced Oct 28, 2026, 6:34 PM EDT
Completed Phase 2 Interventional Results available

Acetaminophen and Ascorbate in Sepsis: Targeted Therapy to Enhance Recovery

NCT04291508
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Critical Illness, Respiratory Failure, Sepsis
Interventions
Intravenous Acetaminophen (room temperature), Intravenous Vitamin C (refrigerated), 5% Dextrose (room temperature), 5% Dextrose refrigerated
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
41
States / cities
Birmingham, Alabama • Tucson, Arizona • Fresno, California + 34 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2024 · Synced Oct 28, 2026, 6:34 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

NCT06356571
View directory record Official record
Conditions
Plasma Cell Myeloma Refractory
Interventions
Isatuximab SC-OBDS, Montelukast, Dexamethasone, Acetaminophen, Diphenhydramine, Methylprednisolone, Carfilzomib
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
34
States / cities
Phoenix, Arizona • Los Angeles, California • West Hollywood, California + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 28, 2026, 6:34 PM EDT
Terminated Phase 1 Interventional Results available

Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Adults With Refractory Large B-cell Lymphoma

NCT03704298
View directory record Official record
Conditions
Relapsed/Refractory Large B-cell Lymphoma
Interventions
Cyclophosphamide, Fludarabine, Axicabtagene Ciloleucel, Utomilumab
Drug · Biological
Lead sponsor
Kite, A Gilead Company
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
5
States / cities
Palo Alto, California • Santa Monica, California • Tampa, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2024 · Synced Oct 28, 2026, 6:34 PM EDT
Completed Not applicable Interventional Results available

The Effect of Intravenous Lidocaine on Allodynia

NCT00659633
View directory record Official record
Conditions
Pain
Interventions
lidocaine
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Oct 28, 2026, 6:34 PM EDT
Terminated Phase 3 Interventional Results available

Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

NCT04329949
View directory record Official record
Conditions
Metastatic Pancreatic Ductal Adenocarcinoma
Interventions
Relacorilant, 100 mg and 25 mg, Nab-paclitaxel
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
18
States / cities
Scottsdale, Arizona • Duarte, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 28, 2026, 6:34 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer

NCT03711058
View directory record Official record
Conditions
Unresectable or Metastatic Microsatellite Stable (MSS) Solid Tumor, Microsatellite Stable (MSS) Colon Cancer
Interventions
Copanlisib, Nivolumab
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Oct 28, 2026, 6:34 PM EDT
Completed Phase 1Phase 2 Interventional

Study of CR011-vcMMAE to Treat Locally Advanced or Metastatic Breast Cancer

NCT00704158
View directory record Official record
Conditions
Breast Cancer
Interventions
CR011-vcMMAE
Drug
Lead sponsor
CuraGen Corporation
Industry
Eligibility
18 Years and older · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
5
States / cities
Fort Myers, Florida • Lake Worth, Florida • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2015 · Synced Oct 28, 2026, 6:34 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety and Pharmacokinetics of a Human Monoclonal Antibody (VH4527079) in Healthy Adults and Persons With HIV

NCT06652958
View directory record Official record
Conditions
HIV Infections
Interventions
VH4527079
Biological
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 28, 2026, 6:34 PM EDT
Terminated Phase 2 Interventional

Infliximab in Treating Cancer-Related Fatigue in Postmenopausal Women Who Have Undergone Treatment for Breast Cancer

NCT00112749
View directory record Official record
Conditions
Breast Cancer, Fatigue
Interventions
infliximab, Clinical Assessment, Self-report questionnaires, Immune Assessment
Biological · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
45 Years to 65 Years · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 31, 2020 · Synced Oct 28, 2026, 6:34 PM EDT
Completed No phase listed Observational

Chemotherapeutic Agents in Brain/Breast

NCT00795678
View directory record Official record
Conditions
Breast Cancer, Metastatic Cancer
Interventions
capecitabine, cyclophosphamide, doxorubicin hydrochloride, gemcitabine hydrochloride, lapatinib ditosylate, paclitaxel, vinorelbine ditartrate, Trastuzumab
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
2
States / cities
New York, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 2, 2013 · Synced Oct 28, 2026, 6:34 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase I/II Trial of S64315 Plus Azacitidine in Acute Myeloid Leukaemia

NCT04629443
View directory record Official record
Conditions
Acute Myeloid Leukaemia
Interventions
S 64315 (also referred as MIK665) and azacitidine
Drug
Lead sponsor
Institut de Recherches Internationales Servier
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 6, 2024 · Synced Oct 28, 2026, 6:34 PM EDT
Completed Not applicable Interventional

Autologous Transplant Using Dose-Escalated Total Body Irradiation & Cyclophosphamide & Palifermin for NHL

NCT03042585
View directory record Official record
Conditions
Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma
Interventions
Total body irradiation
Radiation
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2018
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 21, 2019 · Synced Oct 28, 2026, 6:34 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Low-dose Propofol for Pediatric Migraine

NCT01604785
View directory record Official record
Conditions
Migraine Headache
Interventions
Propofol, Standard Treatment
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
7 Years to 18 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 31, 2018 · Synced Oct 28, 2026, 6:34 PM EDT
Completed Phase 2 Interventional Results available

Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian

NCT04374630
View directory record Official record
Conditions
Platinum-resistant Ovarian Cancer
Interventions
Paclitaxel, Afuresertib
Drug
Lead sponsor
Laekna Limited
Industry
Eligibility
18 Years and older · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
30
States / cities
Phoenix, Arizona • Tucson, Arizona • Rogers, Arkansas + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 28, 2026, 6:34 PM EDT
Completed Phase 2 Interventional Results available

Safety and Pharmacokinetics of Ifetroban in Hepatorenal Syndrome Patients

NCT01436500
View directory record Official record
Conditions
Hepatorenal Syndrome
Interventions
Ifetroban Injection, Placebo
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
11
States / cities
Phoenix, Arizona • La Jolla, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2017 · Synced Oct 28, 2026, 6:34 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma

NCT01508936
View directory record Official record
Conditions
Eosinophilic Asthma
Interventions
Reslizumab, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
66
States / cities
Birmingham, Alabama • Homewood, Alabama • Jasper, Alabama + 58 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2016 · Synced Oct 28, 2026, 6:34 PM EDT
Active, not recruiting Phase 1 Interventional

T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia

NCT03531736
View directory record Official record
Conditions
Myeloid Diseases
Interventions
Antithymocyte globulin (Rabbit), fludarabine, total body irradiation, cyclophosphamide, Rituxan, Allogeneic Hematopoietic Stem Cell Transplantation
Drug · Radiation · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
2
States / cities
Middletown, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 28, 2026, 6:34 PM EDT